A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context
Summary: Background: Long-term treatment with immunosuppressants is necessary to attenuate allograft rejection following organ transplantation (OT). Consequently, the overall survival of OT recipients with malignancies has been substantially compromised by tumour recurrence. Rapamycin (RAPA) is a c...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396423001597 |
| _version_ | 1797829529663700992 |
|---|---|
| author | Zhentao Yang Haiyang Xie Jianqin Wan Yuchen Wang Liang Zhang Ke Zhou Hong Tang Wentao Zhao Hangxiang Wang Penghong Song Shusen Zheng |
| author_facet | Zhentao Yang Haiyang Xie Jianqin Wan Yuchen Wang Liang Zhang Ke Zhou Hong Tang Wentao Zhao Hangxiang Wang Penghong Song Shusen Zheng |
| author_sort | Zhentao Yang |
| collection | DOAJ |
| description | Summary: Background: Long-term treatment with immunosuppressants is necessary to attenuate allograft rejection following organ transplantation (OT). Consequently, the overall survival of OT recipients with malignancies has been substantially compromised by tumour recurrence. Rapamycin (RAPA) is a clinically approved immunosuppressive agent with antitumour activity that is considered beneficial in preventing posttransplant tumour recurrence. However, the clinical outcome of RAPA is impeded by acquired drug resistance and its poor oral bioavailability. Methods: A nanotherapeutic strategy was developed by supramolecular assembly of RAPA into a polymer cytotoxic 7-ethyl-10-hydroxycamptothecin (SN38) prodrug nanoparticle (termed SRNP) for simultaneous codelivery of cytotoxic/immunosuppressive agents. Cell-based experiments were used to evaluate the cytotoxicity of SRNPs against hepatocellular carcinoma (HCC). The therapeutic efficacy of SRNPs was evaluated in multiple preclinical models including an orthotopic HCC mouse model, an orthotopic liver transplantation (OLT) rat model and a clinically relevant cancer-transplant model to examine its antitumour and immunosuppressive activity. Findings: The combination of SN38 with RAPA resulted in synergetic effects against HCC cells and alleviated RAPA resistance by abrogating Akt/mTOR signalling activation. SRNPs exhibited potent antitumour efficiency in the orthotopic HCC model while substantially prolonging the survival of allografts in the OLT model. In the cancer-transplant model that simultaneously bears tumour xenografts and skin allografts, SRNPs not only effectively inhibited tumour growth but also attenuated allograft damage. Interpretation: The nanotherapy presented here had enhanced efficacy against tumours and maintained satisfactory immunosuppressive activity and thus has great potential to improve the survival outcomes of patients with a high risk of tumour recurrence following OT. Funding: This work was supported by the National Natural Science Foundation of China (32171368 and 31671019), the Zhejiang Provincial Natural Science Foundation of China (LZ21H180001), the Zhejiang Province Preeminence Youth Fund (LR19H160002), and the Jinan Provincial Laboratory Research Project of Microecological Biomedicine (JNL-2022039c). |
| first_indexed | 2024-04-09T13:21:43Z |
| format | Article |
| id | doaj.art-12f4aa1a9e144b648e9502e2ce75d74c |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-04-09T13:21:43Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-12f4aa1a9e144b648e9502e2ce75d74c2023-05-11T04:24:11ZengElsevierEBioMedicine2352-39642023-06-0192104594A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in contextZhentao Yang0Haiyang Xie1Jianqin Wan2Yuchen Wang3Liang Zhang4Ke Zhou5Hong Tang6Wentao Zhao7Hangxiang Wang8Penghong Song9Shusen Zheng10Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China; Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou 310003, China; Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou 310003, Zhejiang Province, China; Corresponding author. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qinchun Road, Hangzhou 310003, China.Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China; Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou 310003, China; Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou 310003, Zhejiang Province, China; Corresponding author. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qinchun Road, Hangzhou 310003, China.Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China; Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou 310003, China; Key Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou 310003, Zhejiang Province, China; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China; Corresponding author. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qinchun Road, Hangzhou 310003, China.Summary: Background: Long-term treatment with immunosuppressants is necessary to attenuate allograft rejection following organ transplantation (OT). Consequently, the overall survival of OT recipients with malignancies has been substantially compromised by tumour recurrence. Rapamycin (RAPA) is a clinically approved immunosuppressive agent with antitumour activity that is considered beneficial in preventing posttransplant tumour recurrence. However, the clinical outcome of RAPA is impeded by acquired drug resistance and its poor oral bioavailability. Methods: A nanotherapeutic strategy was developed by supramolecular assembly of RAPA into a polymer cytotoxic 7-ethyl-10-hydroxycamptothecin (SN38) prodrug nanoparticle (termed SRNP) for simultaneous codelivery of cytotoxic/immunosuppressive agents. Cell-based experiments were used to evaluate the cytotoxicity of SRNPs against hepatocellular carcinoma (HCC). The therapeutic efficacy of SRNPs was evaluated in multiple preclinical models including an orthotopic HCC mouse model, an orthotopic liver transplantation (OLT) rat model and a clinically relevant cancer-transplant model to examine its antitumour and immunosuppressive activity. Findings: The combination of SN38 with RAPA resulted in synergetic effects against HCC cells and alleviated RAPA resistance by abrogating Akt/mTOR signalling activation. SRNPs exhibited potent antitumour efficiency in the orthotopic HCC model while substantially prolonging the survival of allografts in the OLT model. In the cancer-transplant model that simultaneously bears tumour xenografts and skin allografts, SRNPs not only effectively inhibited tumour growth but also attenuated allograft damage. Interpretation: The nanotherapy presented here had enhanced efficacy against tumours and maintained satisfactory immunosuppressive activity and thus has great potential to improve the survival outcomes of patients with a high risk of tumour recurrence following OT. Funding: This work was supported by the National Natural Science Foundation of China (32171368 and 31671019), the Zhejiang Provincial Natural Science Foundation of China (LZ21H180001), the Zhejiang Province Preeminence Youth Fund (LR19H160002), and the Jinan Provincial Laboratory Research Project of Microecological Biomedicine (JNL-2022039c).http://www.sciencedirect.com/science/article/pii/S2352396423001597Organ transplantationHepatocellular carcinomaTumour recurrenceNanotherapeutic strategy |
| spellingShingle | Zhentao Yang Haiyang Xie Jianqin Wan Yuchen Wang Liang Zhang Ke Zhou Hong Tang Wentao Zhao Hangxiang Wang Penghong Song Shusen Zheng A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context EBioMedicine Organ transplantation Hepatocellular carcinoma Tumour recurrence Nanotherapeutic strategy |
| title | A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context |
| title_full | A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context |
| title_fullStr | A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context |
| title_full_unstemmed | A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context |
| title_short | A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context |
| title_sort | nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationresearch in context |
| topic | Organ transplantation Hepatocellular carcinoma Tumour recurrence Nanotherapeutic strategy |
| url | http://www.sciencedirect.com/science/article/pii/S2352396423001597 |
| work_keys_str_mv | AT zhentaoyang ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT haiyangxie ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT jianqinwan ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT yuchenwang ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT liangzhang ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT kezhou ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT hongtang ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT wentaozhao ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT hangxiangwang ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT penghongsong ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT shusenzheng ananotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT zhentaoyang nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT haiyangxie nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT jianqinwan nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT yuchenwang nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT liangzhang nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT kezhou nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT hongtang nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT wentaozhao nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT hangxiangwang nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT penghongsong nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext AT shusenzheng nanotherapeuticstrategythatengagescytotoxicandimmunosuppressiveactivitiesforthetreatmentofcancerrecurrencefollowingorgantransplantationresearchincontext |